Weight reduction in schizophrenics by molindone



	Full Text (PDF)
	Alert me when this article is cited
	Alert me if a correction is posted



	Email this article to a Colleague
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new issues of the journal
	Add to My Articles & Searches
	Download to citation manager



	Citing Articles via HighWire
	Citing Articles via Google Scholar



	Articles by Gardos, G.
	Articles by Cole, J. O.
	Search for Related Content



	PubMed Citation
	Articles by Gardos, G.
	Articles by Cole, J. O.

Am J Psychiatry 1977; 134:302-304
Copyright © 1977 by American Psychiatric Association

REGULAR ARTICLES

Weight reduction in schizophrenics by molindone

G Gardos and JO Cole

The weight-reducing property of molindone, a recently introduced antipsychotic drug, was tested in 9 hospitalized chronic schizophrenic patients. There was an average weight loss of 7.6 kg after 3 months on molindone; most of the loss occurred during the first month. The mechanism producing this weight loss is uncertain, but a central anorexigenic effect may be an important factor.

This article has been cited by other articles:

J. M. Noel
ASHP Therapeutic Position Statement on the Use of Second-Generation Antipsychotic Medications in the Treatment of Adults with Psychotic Disorders
Am. J. Health Syst. Pharm., April 15, 2007; 64(8): 863 - 876.
[Full Text] [PDF]

Y. Vanina, A. Podolskaya, K. Sedky, H. Shahab, A. Siddiqui, F. Munshi, and S. Lippmann
Body Weight Changes Associated With Psychopharmacology
Psychiatr Serv, July 1, 2002; 53(7): 842 - 847.
[Abstract] [Full Text] [PDF]

D. B. Allison, J. L. Mentore, M. Heo, L. P. Chandler, J. C. Cappelleri, M. C. Infante, and P. J. Weiden
Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis
Am J Psychiatry, November 1, 1999; 156(11): 1686 - 1696.
[Abstract] [Full Text]

Get information about faster international access.